Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $90
Haemonetics Corporation
Haemonetics Corporation HAE | 0.00 |
Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:
HAE) with a Outperform and raises the price target from $85 to $90.